• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Clinical and Translational Science >Real‐world evidence of population differences in allopurinol‐related severe cutaneous adverse reactions in East Asians: A population‐based cohort study
【2h】

Real‐world evidence of population differences in allopurinol‐related severe cutaneous adverse reactions in East Asians: A population‐based cohort study

机译：欧妥嘌呤醇相关严重皮肤不良反应的人口差异的现实世界：基于人群的队列研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Allopurinol‐related severe cutaneous adverse reactions (SCARs) are strongly associated with HLA‐B*58:01, the allele frequency (AF) of which is largely different among East Asians. However, evidence of population differences in SCAR development and relevance of genetic and/or other risk factors in the real‐world remain unelucidated. This study aimed to evaluate population differences in allopurinol‐related SCAR incidence related to genetic and/or other risk factors among East Asians in the real‐world. A population‐based cohort study was conducted using claims databases from Taiwan, Korea, and Japan. New users of allopurinol (311,846; 868,221; and 18,052 in Taiwan, Korea, and Japan, respectively) were followed up to 1 year. As control drugs, phenytoin and carbamazepine were used. The crude incidence rate ratios (IRRs) of SCARs for allopurinol against phenytoin or carbamazepine were the highest in Taiwan (IRR, 0.62 and 1.22; 95% confidence interval [CI], 0.54–0.72 and 1.01–1.47, respectively), followed by Korea (IRR, 0.34 and 0.82; 95% CI, 0.29–0.40 and 0.77–0.87), and the lowest in Japan (IRR, 0.04 and 0.16; 95% CI, 0.02–0.08 and 0.09–0.29). This order was accordant with that of AF ratios (AFRs) reported of HLA‐B*58:01 against alleles responsible for phenytoin‐ or carbamazepine‐related SCARs. The IRRs were higher in patients with chronic kidney disease, females, and elderly. This study demonstrated population differences in the risk of allopurinol‐related SCAR development among East Asians based on genetic and other common risk factors. This finding will help to promote appropriate risk management for allopurinol‐related SCARs based on ethnic origins.
机译：01，等位基因频率（AF）其中是东亚人之间有很大的不同：别嘌醇相关的重度皮肤不良反应（疤痕）强烈与HLA-B * 58相关联。然而，在SCAR发展和现实世界的基因和/或其他风险因素的相关性差异的人口仍然证据unelucidated。本研究旨在评估在真实世界与遗传和/或其他危险因素东方人中别嘌醇相关的SCAR发病人群的差异。以人口为基础的队列研究使用索赔数据库来自台湾，韩国和日本进行。别嘌醇的新用户（311846; 868221;和18052在台湾，韩国和日本，分别），随访1年。作为对照药，苯妥英钠和卡马西平使用。疤痕针对苯妥英卡马西平或别嘌呤醇的粗发病率比（内部收益率）为在台湾最高（IRR，0.62和1.22; 95％置信区间[CI]，0.54-0.72和1.01-1.47，分别地），其次是韩国（IRR，0.34和0.82; 95％CI，0.29-0.40和0.77-0.87），和在日本最低（IRR，0.04和0.16; 95％CI，0.02-0.08和0.09-0.29）。这个顺序是一致的与报道的HLA-B * 58的AF比（AFRS）的：01对负责phenytoin-或卡马西平相关的疤痕等位基因。该内部回报均较高的患者有慢性肾脏疾病，女性和老年人。基于遗传等常见危险因素别嘌醇相关SCAR发展的东亚人之间的风险，本研究证实人群的差异。这一发现将有助于推动基于种族别嘌醇相关的疤痕适当的风险管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号